Animal Model
Preclinical Disease Models for Cancers and Inflammation
Axela provides a comprehensive range of in vivo disease models to evaluate drug efficacy, safety, and mechanisms of action. Our models include both cancer and inflammation systems, enabling accurate preclinical assessment of therapeutic candidates, prediction of clinical outcomes, and support for translational research in oncology and immunology.
Cancer Models
Inflammation Models
Patient-derived xenograft (PDX) and other xenograft models using human cancer cells or cell lines
Angiogenesis models in mice and zebrafish
Microbiopsy sampling and real-time monitoring of tumor response and drug toxicity
Rheumatoid arthritis (AIA, CIA)
Autoimmune encephalomyelitis (EAE)
Asthma and inflammatory bowel disease (IBD) models
Delayed-type hypersensitivity and dermatitis (FITC-induced) models
Psoriasis (imiquimod-induced)
Pulmonary fibrosis (bleomycin-induced)
Cancer cells or tumor tissues grown in culture can be implanted into mice through various methods, including subcutaneous injection, intravenous injection, or intranasal delivery. These approaches allow the establishment of xenograft or metastatic tumor models for studying cancer progression and evaluating drug efficacy.